Equities

Smith & Nephew PLC

SN.:LSE

Smith & Nephew PLC

Health CareMedical Equipment and Services
  • Price (GBX)1,267.00
  • Today's Change-26.50 / -2.05%
  • Shares traded2.15m
  • 1 Year change23.61%
  • Beta1.0587
Data delayed at least 20 minutes, as of Feb 06 2026 16:35 GMT.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 05-Feb-26
Select bar for recommendation details.
Recommendations05-Feb-26
Buy5
Outperform4
Hold9
Sell0
Strong Sell0

Share price forecast

The 15 analysts offering 12 month price targets for Smith & Nephew plc have a median target of 1,412.57, with a high estimate of 1,664.63 and a low estimate of 1,210.78. The median estimate represents a 9.21% increase from the last price of 1,293.50.
High28.7%1,664.63
Med9.2%1,412.57
Low-6.4%1,210.78

Dividends

In 2024, Smith & Nephew PLC reported a dividend of 0.36 USD, which represents a 7.54% decrease from last year. The 18 analysts covering the company expect dividends of 0.41 USD for the upcoming fiscal year, an increase of 15.78%.
Div growth (TTM)-7.54%
More ▼

Earnings history & estimates

On Feb 05, 2015, earnings of 0.26 per share. This result was in line with the consensus of the 4 analysts following the company
The next earnings announcement is expected on Mar 02, 2026.
Average growth rate+5.12%
Smith & Nephew plc reported annual 2024 earnings of 0.84 per share on Feb 25, 2025.
Average growth rate+7.07%
More ▼

Revenue history & estimates

Smith & Nephew plc had 3rd quarter 2025 revenues of 1.50bn. This missed the 1.52bn consensus estimate of the 3 analysts following the company. This was 8.30% above the prior year's 3rd quarter results.
Average growth rate+1.96%
Smith & Nephew plc had revenues for the full year 2024 of 5.81bn. This was 4.70% above the prior year's results.
Average growth rate+6.37%
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.